Oncolytics Biotech (ONC) Competitors C$0.98 +0.05 (+5.38%) As of 03:59 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesBuy This Stock ONC vs. ABCN, EMC, FRX, BCT, IPA, TH, SCYB, COM, NVH, and IGXShould you be buying Oncolytics Biotech stock or one of its competitors? The main competitors of Oncolytics Biotech include VIVO Cannabis (ABCN), Emblem (EMC), Fennec Pharmaceuticals (FRX), BriaCell Therapeutics (BCT), ImmunoPrecise Antibodies (IPA), Theratechnologies (TH), Scythian Biosciences (SCYB), 138267 (COM.TO) (COM), Novoheart (NVH), and IntelGenx Technologies (IGX). These companies are all part of the "biotechnology" industry. Oncolytics Biotech vs. Its Competitors VIVO Cannabis Emblem Fennec Pharmaceuticals BriaCell Therapeutics ImmunoPrecise Antibodies Theratechnologies Scythian Biosciences 138267 (COM.TO) Novoheart IntelGenx Technologies Oncolytics Biotech (TSE:ONC) and VIVO Cannabis (CVE:ABCN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, profitability, institutional ownership, risk, dividends and earnings. Do insiders and institutionals hold more shares of ONC or ABCN? 1.8% of Oncolytics Biotech shares are owned by institutional investors. 3.8% of Oncolytics Biotech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Do analysts prefer ONC or ABCN? Oncolytics Biotech currently has a consensus target price of C$3.50, suggesting a potential upside of 257.14%. Given Oncolytics Biotech's stronger consensus rating and higher probable upside, research analysts clearly believe Oncolytics Biotech is more favorable than VIVO Cannabis.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Oncolytics Biotech 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00VIVO Cannabis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ONC or ABCN? In the previous week, Oncolytics Biotech had 4 more articles in the media than VIVO Cannabis. MarketBeat recorded 4 mentions for Oncolytics Biotech and 0 mentions for VIVO Cannabis. VIVO Cannabis' average media sentiment score of 0.00 beat Oncolytics Biotech's score of -0.94 indicating that VIVO Cannabis is being referred to more favorably in the news media. Company Overall Sentiment Oncolytics Biotech Negative VIVO Cannabis Neutral Which has stronger earnings and valuation, ONC or ABCN? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOncolytics BiotechN/AN/A-C$27.66M-C$0.36-2.73VIVO CannabisN/AN/AN/AN/AN/A Is ONC or ABCN more profitable? VIVO Cannabis' return on equity of 0.00% beat Oncolytics Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Oncolytics BiotechN/A -141.94% -71.33% VIVO Cannabis N/A N/A N/A SummaryOncolytics Biotech beats VIVO Cannabis on 5 of the 8 factors compared between the two stocks. Get Oncolytics Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ONC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart ONC vs. The Competition Export to ExcelMetricOncolytics BiotechBiotechnology IndustryMedical SectorTSE ExchangeMarket CapC$75.53MC$122.96MC$5.43BC$6.13BDividend Yield0.31%3.74%5.37%6.72%P/E Ratio-2.733.2725.6246.58Price / SalesN/A3,966.20374.24997.17Price / Cash4.2213.1936.0083.29Price / Book8.3343.337.864.67Net Income-C$27.66M-C$92.79MC$3.15BC$301.20M7 Day Performance1.03%-0.07%1.27%0.64%1 Month Performance68.97%1.73%5.50%4.55%1 Year Performance-30.99%178.54%39.41%26.93% Oncolytics Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ONCOncolytics Biotech0.7545 of 5 starsC$0.98+5.4%C$3.50+257.1%-32.1%C$75.53MN/A-2.7329News CoverageGap UpHigh Trading VolumeABCNVIVO CannabisN/AC$1.32+5.6%N/A+0.0%C$256.62MN/A0.00N/AGap UpEMCEmblemN/A$1.88+1.6%N/A+0.0%$245.45M$5.71M-9.89N/AFRXFennec PharmaceuticalsN/AC$10.45-5.9%N/A+39.1%C$201.53MC$34.86M-177.0210BCTBriaCell TherapeuticsN/AC$10.60-3.8%C$15.00+41.5%+0.0%C$168.68MN/A-28.195News CoverageIPAImmunoPrecise AntibodiesN/AC$6.50+0.8%N/A+0.0%C$162.08MC$19.47M-7.3080Gap DownTHTheratechnologiesN/AC$3.36+2.4%N/A+88.8%C$107.20MC$52.22M-38.03103News CoverageSCYBScythian BiosciencesN/AC$3.49-5.9%N/A+0.0%C$102.38MN/A0.00N/AHigh Trading VolumeCOM138267 (COM.TO)N/AN/AN/AN/AC$102.19MN/A0.00N/ANVHNovoheartN/AC$0.53+1.9%N/A+0.0%C$99.98MC$423.50K-13.95N/AIGXIntelGenx TechnologiesN/AC$0.58+1.8%N/A+0.0%C$87.32MC$1.75M-7.442,050Gap Up Related Companies and Tools Related Companies VIVO Cannabis Alternatives Emblem Alternatives Fennec Pharmaceuticals Alternatives BriaCell Therapeutics Alternatives ImmunoPrecise Antibodies Alternatives Theratechnologies Alternatives Scythian Biosciences Alternatives 138267 (COM.TO) Alternatives Novoheart Alternatives IntelGenx Technologies Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (TSE:ONC) was last updated on 6/26/2025 by MarketBeat.com Staff From Our PartnersWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredWhy July is critical for your stocksBig Study Shows Stocks Extremely Likely to Crash in 2026? Legendary quant analyst Marc Chaikin says in 50 y...Chaikin Analytics | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredTrump: "Buy Stocks Now!" (Here's a Better Move)Trump: "Buy Stocks Now!" (Here's a Better Move) President Trump just announced from the Oval Office: "You b...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oncolytics Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Oncolytics Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ONC Stock Free ONC Stock Alerts